Traws Pharma Earnings Call Transcripts
Fiscal Year 2026
-
The meeting established a quorum and approved all five proposals, including director elections, incentive plan amendments, auditor ratification, and share issuance upon warrant exercise. No shareholder questions were received during the session.
Fiscal Year 2025
-
Significant progress was made advancing a next-gen influenza antiviral, supported by $60M in new financing. Net income turned positive in 2025, and key clinical studies are planned in the UK, while US trials face an FDA clinical hold pending toxicology data resolution.
-
Advanced COVID-19 and influenza antiviral programs, with phase II ratutrelvir results expected by year-end 2025. Revenue rose sharply due to deferred licensing income, and net loss narrowed significantly year-over-year. Bird flu study deferred amid low incidence, but regulatory approvals position for rapid response.
Fiscal Year 2024
-
Two antiviral candidates showed strong preclinical and early clinical results: tivoxavir marboxil for bird flu (single-dose, broad resistance, long-acting) and ratutrelvir for COVID (potent, ritonavir-independent, 10-day regimen). Cash reserves support operations into Q1 2026.
-
Q2 2024 saw a major merger, expanded pipeline, and a net loss of $123.1M due to a non-cash R&D charge. Key clinical milestones for influenza, COVID-19, and oncology programs are expected in late 2024, with cash runway projected through year-end.